Loading…
Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium
Intravenous formulations of epoprostenol are frequently delivered via nebulizer to treat pulmonary hypertension in acutely ill patients. Although their efficacy as pulmonary vasodilators has been shown to be comparable to inhaled nitric oxide, the local effects of these formulations within the airwa...
Saved in:
Published in: | Respiratory care 2020-10, Vol.65 (10), p.1427-1432 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c388t-1dbc86c1d5a997f0bdc8edfa5602e1bd3dc7c1dc7dde3be1b9e39d3ed38de1a73 |
container_end_page | 1432 |
container_issue | 10 |
container_start_page | 1427 |
container_title | Respiratory care |
container_volume | 65 |
creator | Kuch, Bradley A Linssen, Rosalie Yoshikawa, Hiroki Smallwood, Craig D Davis, Michael D |
description | Intravenous formulations of epoprostenol are frequently delivered via nebulizer to treat pulmonary hypertension in acutely ill patients. Although their efficacy as pulmonary vasodilators has been shown to be comparable to inhaled nitric oxide, the local effects of these formulations within the airways have not been determined. We hypothesized that the alkaline diluents of these compounds would lead to increased airway epithelial cell death and ciliary cessation.
Human bronchial epithelial cells were exposed to epoprostenol in glycine and arginine diluents or control fluid. Ciliary beat frequency, lactate dehydrogenase, and total RNA levels were measured before and after exposure. Results were compared between exposure and control groups.
Ciliary beat frequency ceased immediately after exposure to epoprostenol with both diluents. Lactate dehydrogenase levels increased by 200% after exposure to epoprostenol and glycine diluent (
= .002). Total RNA levels were undetectable after exposure to epoprostenol and arginine, indicating complete cell death and lysis (
= .015). Ciliary beat frequency ceased after 30 s of exposure to epoprostenol and glycine (
= .008). There was no difference between cells exposed to epoprostenol and those exposed only to diluent.
Exposure to intravenous formulations of epoprostenol in glycine and arginine caused increased cell death and ciliary cessation in bronchial epithelial cells. These findings suggest that undesired local effects may occur when these compounds are delivered as inhaled aerosols to patients. |
doi_str_mv | 10.4187/respcare.07938 |
format | article |
fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A638437453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A638437453</galeid><sourcerecordid>A638437453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-1dbc86c1d5a997f0bdc8edfa5602e1bd3dc7c1dc7dde3be1b9e39d3ed38de1a73</originalsourceid><addsrcrecordid>eNptUc1LwzAUD6K4Ob16lILgrTNp-pEex9h0MNDD9CSUNHlxkbYpSevYf2_cnCiMd3i89_vg8X4IXRM8jgnL7i24VnALY5zllJ2gIcljGtI0iU_REOMIh4RG8QBdOPfhxzRO8nM0oFFCGGZsiN6WRvAqmCkFonOBUcFqY4JF01n-CY3pXTA3tu4r3mnT7PDnvqpNw-02eOXOSO0hYz3SBBNtN3wbzFrdraHSfX2JzhSvHFz99BF6mc9W08dw-fSwmE6WoaCMdSGRpWCpIDLheZ4pXErBQCqepDgCUkoqReZRkUkJtPSbHGguKUjKJBCe0RG63fu-8woK3Sjjzxe1dqKYpJTFNIsT6lnjIyxfEmotTANK-_0_wd0fwRp41a2dqfrdK446C2ucs6CK1urav6gguPiOqTjEVOxi8oKbvaDtyxrkL_2QC_0C2BiQ-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium</title><source>Open Access: PubMed Central</source><creator>Kuch, Bradley A ; Linssen, Rosalie ; Yoshikawa, Hiroki ; Smallwood, Craig D ; Davis, Michael D</creator><creatorcontrib>Kuch, Bradley A ; Linssen, Rosalie ; Yoshikawa, Hiroki ; Smallwood, Craig D ; Davis, Michael D</creatorcontrib><description>Intravenous formulations of epoprostenol are frequently delivered via nebulizer to treat pulmonary hypertension in acutely ill patients. Although their efficacy as pulmonary vasodilators has been shown to be comparable to inhaled nitric oxide, the local effects of these formulations within the airways have not been determined. We hypothesized that the alkaline diluents of these compounds would lead to increased airway epithelial cell death and ciliary cessation.
Human bronchial epithelial cells were exposed to epoprostenol in glycine and arginine diluents or control fluid. Ciliary beat frequency, lactate dehydrogenase, and total RNA levels were measured before and after exposure. Results were compared between exposure and control groups.
Ciliary beat frequency ceased immediately after exposure to epoprostenol with both diluents. Lactate dehydrogenase levels increased by 200% after exposure to epoprostenol and glycine diluent (
= .002). Total RNA levels were undetectable after exposure to epoprostenol and arginine, indicating complete cell death and lysis (
= .015). Ciliary beat frequency ceased after 30 s of exposure to epoprostenol and glycine (
= .008). There was no difference between cells exposed to epoprostenol and those exposed only to diluent.
Exposure to intravenous formulations of epoprostenol in glycine and arginine caused increased cell death and ciliary cessation in bronchial epithelial cells. These findings suggest that undesired local effects may occur when these compounds are delivered as inhaled aerosols to patients.</description><identifier>ISSN: 0020-1324</identifier><identifier>EISSN: 1943-3654</identifier><identifier>DOI: 10.4187/respcare.07938</identifier><identifier>PMID: 32518088</identifier><language>eng</language><publisher>United States: Daedalus Enterprises, Inc</publisher><subject>Administration, Inhalation ; Analysis ; Antihypertensive Agents - adverse effects ; Care and treatment ; Cell death ; Epithelium ; Epoprostenol ; Epoprostenol - therapeutic use ; Glycine ; Humans ; Hypertension ; Hypertension, Pulmonary - drug therapy ; Nitric oxide ; Nitric Oxide - therapeutic use ; RNA ; Vasodilation ; Vasodilator Agents</subject><ispartof>Respiratory care, 2020-10, Vol.65 (10), p.1427-1432</ispartof><rights>Copyright © 2020 by Daedalus Enterprises.</rights><rights>COPYRIGHT 2020 Daedalus Enterprises, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c388t-1dbc86c1d5a997f0bdc8edfa5602e1bd3dc7c1dc7dde3be1b9e39d3ed38de1a73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32518088$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuch, Bradley A</creatorcontrib><creatorcontrib>Linssen, Rosalie</creatorcontrib><creatorcontrib>Yoshikawa, Hiroki</creatorcontrib><creatorcontrib>Smallwood, Craig D</creatorcontrib><creatorcontrib>Davis, Michael D</creatorcontrib><title>Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium</title><title>Respiratory care</title><addtitle>Respir Care</addtitle><description>Intravenous formulations of epoprostenol are frequently delivered via nebulizer to treat pulmonary hypertension in acutely ill patients. Although their efficacy as pulmonary vasodilators has been shown to be comparable to inhaled nitric oxide, the local effects of these formulations within the airways have not been determined. We hypothesized that the alkaline diluents of these compounds would lead to increased airway epithelial cell death and ciliary cessation.
Human bronchial epithelial cells were exposed to epoprostenol in glycine and arginine diluents or control fluid. Ciliary beat frequency, lactate dehydrogenase, and total RNA levels were measured before and after exposure. Results were compared between exposure and control groups.
Ciliary beat frequency ceased immediately after exposure to epoprostenol with both diluents. Lactate dehydrogenase levels increased by 200% after exposure to epoprostenol and glycine diluent (
= .002). Total RNA levels were undetectable after exposure to epoprostenol and arginine, indicating complete cell death and lysis (
= .015). Ciliary beat frequency ceased after 30 s of exposure to epoprostenol and glycine (
= .008). There was no difference between cells exposed to epoprostenol and those exposed only to diluent.
Exposure to intravenous formulations of epoprostenol in glycine and arginine caused increased cell death and ciliary cessation in bronchial epithelial cells. These findings suggest that undesired local effects may occur when these compounds are delivered as inhaled aerosols to patients.</description><subject>Administration, Inhalation</subject><subject>Analysis</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Care and treatment</subject><subject>Cell death</subject><subject>Epithelium</subject><subject>Epoprostenol</subject><subject>Epoprostenol - therapeutic use</subject><subject>Glycine</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - therapeutic use</subject><subject>RNA</subject><subject>Vasodilation</subject><subject>Vasodilator Agents</subject><issn>0020-1324</issn><issn>1943-3654</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNptUc1LwzAUD6K4Ob16lILgrTNp-pEex9h0MNDD9CSUNHlxkbYpSevYf2_cnCiMd3i89_vg8X4IXRM8jgnL7i24VnALY5zllJ2gIcljGtI0iU_REOMIh4RG8QBdOPfhxzRO8nM0oFFCGGZsiN6WRvAqmCkFonOBUcFqY4JF01n-CY3pXTA3tu4r3mnT7PDnvqpNw-02eOXOSO0hYz3SBBNtN3wbzFrdraHSfX2JzhSvHFz99BF6mc9W08dw-fSwmE6WoaCMdSGRpWCpIDLheZ4pXErBQCqepDgCUkoqReZRkUkJtPSbHGguKUjKJBCe0RG63fu-8woK3Sjjzxe1dqKYpJTFNIsT6lnjIyxfEmotTANK-_0_wd0fwRp41a2dqfrdK446C2ucs6CK1urav6gguPiOqTjEVOxi8oKbvaDtyxrkL_2QC_0C2BiQ-w</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Kuch, Bradley A</creator><creator>Linssen, Rosalie</creator><creator>Yoshikawa, Hiroki</creator><creator>Smallwood, Craig D</creator><creator>Davis, Michael D</creator><general>Daedalus Enterprises, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202010</creationdate><title>Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium</title><author>Kuch, Bradley A ; Linssen, Rosalie ; Yoshikawa, Hiroki ; Smallwood, Craig D ; Davis, Michael D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-1dbc86c1d5a997f0bdc8edfa5602e1bd3dc7c1dc7dde3be1b9e39d3ed38de1a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Administration, Inhalation</topic><topic>Analysis</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Care and treatment</topic><topic>Cell death</topic><topic>Epithelium</topic><topic>Epoprostenol</topic><topic>Epoprostenol - therapeutic use</topic><topic>Glycine</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - therapeutic use</topic><topic>RNA</topic><topic>Vasodilation</topic><topic>Vasodilator Agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuch, Bradley A</creatorcontrib><creatorcontrib>Linssen, Rosalie</creatorcontrib><creatorcontrib>Yoshikawa, Hiroki</creatorcontrib><creatorcontrib>Smallwood, Craig D</creatorcontrib><creatorcontrib>Davis, Michael D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Respiratory care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuch, Bradley A</au><au>Linssen, Rosalie</au><au>Yoshikawa, Hiroki</au><au>Smallwood, Craig D</au><au>Davis, Michael D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium</atitle><jtitle>Respiratory care</jtitle><addtitle>Respir Care</addtitle><date>2020-10</date><risdate>2020</risdate><volume>65</volume><issue>10</issue><spage>1427</spage><epage>1432</epage><pages>1427-1432</pages><issn>0020-1324</issn><eissn>1943-3654</eissn><abstract>Intravenous formulations of epoprostenol are frequently delivered via nebulizer to treat pulmonary hypertension in acutely ill patients. Although their efficacy as pulmonary vasodilators has been shown to be comparable to inhaled nitric oxide, the local effects of these formulations within the airways have not been determined. We hypothesized that the alkaline diluents of these compounds would lead to increased airway epithelial cell death and ciliary cessation.
Human bronchial epithelial cells were exposed to epoprostenol in glycine and arginine diluents or control fluid. Ciliary beat frequency, lactate dehydrogenase, and total RNA levels were measured before and after exposure. Results were compared between exposure and control groups.
Ciliary beat frequency ceased immediately after exposure to epoprostenol with both diluents. Lactate dehydrogenase levels increased by 200% after exposure to epoprostenol and glycine diluent (
= .002). Total RNA levels were undetectable after exposure to epoprostenol and arginine, indicating complete cell death and lysis (
= .015). Ciliary beat frequency ceased after 30 s of exposure to epoprostenol and glycine (
= .008). There was no difference between cells exposed to epoprostenol and those exposed only to diluent.
Exposure to intravenous formulations of epoprostenol in glycine and arginine caused increased cell death and ciliary cessation in bronchial epithelial cells. These findings suggest that undesired local effects may occur when these compounds are delivered as inhaled aerosols to patients.</abstract><cop>United States</cop><pub>Daedalus Enterprises, Inc</pub><pmid>32518088</pmid><doi>10.4187/respcare.07938</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0020-1324 |
ispartof | Respiratory care, 2020-10, Vol.65 (10), p.1427-1432 |
issn | 0020-1324 1943-3654 |
language | eng |
recordid | cdi_gale_infotracmisc_A638437453 |
source | Open Access: PubMed Central |
subjects | Administration, Inhalation Analysis Antihypertensive Agents - adverse effects Care and treatment Cell death Epithelium Epoprostenol Epoprostenol - therapeutic use Glycine Humans Hypertension Hypertension, Pulmonary - drug therapy Nitric oxide Nitric Oxide - therapeutic use RNA Vasodilation Vasodilator Agents |
title | Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T16%3A19%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Local%20Effects%20of%20Two%20Intravenous%20Formulations%20of%20Pulmonary%20Vasodilators%20on%20Airway%20Epithelium&rft.jtitle=Respiratory%20care&rft.au=Kuch,%20Bradley%20A&rft.date=2020-10&rft.volume=65&rft.issue=10&rft.spage=1427&rft.epage=1432&rft.pages=1427-1432&rft.issn=0020-1324&rft.eissn=1943-3654&rft_id=info:doi/10.4187/respcare.07938&rft_dat=%3Cgale_cross%3EA638437453%3C/gale_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c388t-1dbc86c1d5a997f0bdc8edfa5602e1bd3dc7c1dc7dde3be1b9e39d3ed38de1a73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32518088&rft_galeid=A638437453&rfr_iscdi=true |